Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01890746
Registration number
NCT01890746
Ethics application status
Date submitted
27/06/2013
Date registered
2/07/2013
Date last updated
11/09/2019
Titles & IDs
Public title
A Safety and Efficacy Study of Eltrombopag in Subjects With AML
Query!
Scientific title
A Randomized, Blinded, Placebo-Controlled, Dose Finding Study to Assess the Safety and Efficacy of the Oral Thrombopoietin Receptor Agonist, Eltrombopag, Administered to Subjects With Acute Myelogenous Leukaemia (AML) Receiving Induction Chemotherapy
Query!
Secondary ID [1]
0
0
2013-000642-20
Query!
Secondary ID [2]
0
0
117146
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Acute Leukaemia
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Leukaemia - Acute leukaemia
Query!
Cancer
0
0
0
0
Query!
Leukaemia - Chronic leukaemia
Query!
Cancer
0
0
0
0
Query!
Children's - Leukaemia & Lymphoma
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Daunorubicin
Treatment: Drugs - Cytarabine
Treatment: Drugs - Eltrombopag
Treatment: Drugs - Placebo
Experimental: Eltrombopag arm - Subjects received induction chemotherapy consisting of daunorubicin bolus intravenous (IV) infusion on Days 1-3 + cytarabine continuous IV infusion on Days 1-7 followed by Eltrombopag once daily orally starting on Day 4 of initial induction chemotherapy. If platelet count was not greater than 100 Gi/L after 7 days the dose was increased until a platelet count of at least 200 Gi/L was achieved/until remission was assessed/ maximum of 42 days from the start of the chemotherapy induction. Subjects who were not aplastic after first cycle of induction chemotherapy received second induction chemotherapy with a modified daunorubicin dose on Days 1-3 + cytarabine on Days 1-7.
Placebo Comparator: Placebo arm - Subject received induction chemotherapy consisting of daunorubicin bolus IV infusion on Days 1-3 + cytarabine continuous IV infusion on Days 1-7 followed by matching placebo once daily oral dose starting on Day 4 of initial induction chemotherapy. If platelet count was not greater than 100 Gi/L after 7 days the matching placebo was given until a platelet count of at least 200 Gi/L was achieved/ until remission was assessed/ maximum of 42 days from the start of the chemotherapy induction. Subjects who were not aplastic after first cycle of induction chemotherapy received a second induction chemotherapy with a modified daunorubicin dose on Days 1-3 + cytarabine on Days 1-7.
Treatment: Drugs: Daunorubicin
For subjects between the ages of 18 and 60 years, 90 mg/m2/day by bolus IV injection through a freshly established free-flowing IV line for 10-15 minutes on days 1, 2, and 3. For subjects > 60 years: daunorubicin dose was adjusted to 60mg /m2.
Treatment: Drugs: Cytarabine
100 mg/m2/day continuous IV infusion on Days 1 through 7.
Treatment: Drugs: Eltrombopag
200 mg orally, once daily, beginning on Day 4 of the first cycle of induction. After 7 days, the dose of the Investigational Product (IP) was to be increased to 300 mg if platelet counts were <100 Gi/L. IP continued until achievement of platelet count of at least 200 Gi/L or assessment of remission of bone marrow status or a maximum of 42 days after initiation of most recent induction. In subjects of East Asian heritage 100 mg orally once daily (a 50% dose reduction) was used and after 7 days, the dose of IP was increased to 150 mg if platelet counts were <100 Gi/L.
Treatment: Drugs: Placebo
Orally, once daily, beginning on Day 4 of the first cycle of induction. After 7 days, the dose given was matching 300 mg Eltrombopag if platelet counts were <100 Gi/L. Placebo continued until achievement of platelet count of at least 200 Gi/L or assessment of remission of bone marrow status or a maximum of 42 days after initiation of most recent induction. In subjects of East Asian heritage placebo matching 100 mg Eltrombopag orally once daily was used and after 7 days, the placebo matching 150 mg Eltrombopag was given if platelet counts were <100 Gi/L.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number of Participants With Any Adverse Events (AE) and Any Serious Adverse Events (SAE) as a Measure of Safety and Tolerability.
Query!
Assessment method [1]
0
0
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, is an important medical event that jeopardizes the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition, or is associated with liver injury and impaired liver function.
Query!
Timepoint [1]
0
0
From the time the first dose of study treatment was administered until 30 days following discontinuation of investigational product regardless of initiation of a new cancer therapy or transfer to hospice
Query!
Primary outcome [2]
0
0
Change From Baseline in the Left Ventricular Ejection Fraction (LVEF).
Query!
Assessment method [2]
0
0
LVEF is a measurement of the percentage of blood leaving heart each time it contracts. LVEF was assessed by an echocardiogram (ECHO) or Multiple Gated Acquisition scan (MUGA). Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Change from Baseline was calculated as the Day 42 value minus the Baseline value.
Query!
Timepoint [2]
0
0
Baseline and Day 42 of the latest chemotherapy cycle (Up to 8 weeks)
Query!
Primary outcome [3]
0
0
Number of Participants With Worst-case Grade Changes From Baseline in the Hematology Parameters
Query!
Assessment method [3]
0
0
The number of participants with a maximum post-baseline grade increase of Grade 3 (G3) or Grade 4 (G4) from their baseline grade are presented. Hematology parameters included only lab tests that are gradable by Common Terminology Criteria for Adverse Events (CTCAE) v4.0.
Query!
Timepoint [3]
0
0
Baseline and up to Day 42 of the latest chemotherapy cycle (Up to 8 weeks)
Query!
Primary outcome [4]
0
0
Number of Participants With Worst-case Grade Changes From Baseline in the Clinical Chemistry Parameters
Query!
Assessment method [4]
0
0
The number of participants with a maximum post-baseline grade increase of Grade 3 or Grade 4 from their baseline grade are presented. Clinical Clinical Chemistry parameters included only lab tests that are gradable by CTCAE v4.0.
Query!
Timepoint [4]
0
0
Baseline and up to Day 42 of the latest chemotherapy cycle (Up to 8 weeks)
Query!
Primary outcome [5]
0
0
Number of Participants With Liver Events.
Query!
Assessment method [5]
0
0
The number of participants with liver enzyme (ALT, AST, ALP, Total bilirubin) abnormalities while receiving study treatment in each arm are presented.
Query!
Timepoint [5]
0
0
8 weeks
Query!
Primary outcome [6]
0
0
Number of Participants With Worst-case Changes From Baseline in Electrocardiogram (ECG) Values
Query!
Assessment method [6]
0
0
The number of participants with worst case post-baseline changes (normal, abnormal - not clinically significant [NCS], abnormal - clinically significant [NS]) in ECG QT prolonged values are presented. The protocol does not define the criteria for normal, abnormal-NCS and abnormal CS ECG. The outcome was based solely on the investigator interpretation of ECG tracings.
Query!
Timepoint [6]
0
0
Baseline and Day 42 of the latest chemotherapy cycle (Up to 8 weeks)
Query!
Primary outcome [7]
0
0
Number of Participants With Worst-case Changes From Baseline in the Eastern Cooperative Oncology Group (ECOG) Performance Status
Query!
Assessment method [7]
0
0
The number of participants with worst case post-baseline changes (improved, no change, deteriorated) are presented.
Query!
Timepoint [7]
0
0
Baseline and Day 42 of the latest chemotherapy cycle (Up to 8 weeks)
Query!
Primary outcome [8]
0
0
Worst-case Change From Baseline in Pulse Rate Values
Query!
Assessment method [8]
0
0
The worst-case post Baseline high and low changes in pulse rate values from Baseline are presented. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Post Baseline is defined as the highest and lowest non-missing post Baseline value respectively. Change from Baseline was calculated as the post Baseline value minus the Baseline value.
Query!
Timepoint [8]
0
0
Baseline and up to Day 42 of the latest chemotherapy cycle (Up to 8 weeks)
Query!
Primary outcome [9]
0
0
Worst-case Post Baseline Change in Blood Pressure Values From Baseline
Query!
Assessment method [9]
0
0
The worst-case post Baseline high changes in systolic blood pressure (SBP) and diastolic blood pressure (DBP) values from Baseline are presented. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Change from Baseline was calculated as the visit value minus the Baseline value.
Query!
Timepoint [9]
0
0
Baseline and up to Day 42 of the latest chemotherapy cycle (Up to 8 weeks)
Query!
Primary outcome [10]
0
0
Worst-case Post Baseline Change in Temperature Values From Baseline
Query!
Assessment method [10]
0
0
The worst-case post Baseline high and low changes in temperature values from Baseline are presented. Baseline was defined as the most recent, non-missing value prior to or on the first study treatment dose date. Post Baseline was defined as the highest and lowest non-missing post Baseline value respectively. Change from Baseline was calculated as the post Baseline value minus the Baseline value.
Query!
Timepoint [10]
0
0
Baseline and up to Day 42 of the latest chemotherapy cycle (Up to 8 weeks)
Query!
Secondary outcome [1]
0
0
Plasma Pharmacokinetics (PK) Parameter of Daunorubicin: Half-life (t1/2)
Query!
Assessment method [1]
0
0
Daunorubicin half-life. PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.
Query!
Timepoint [1]
0
0
Cycle 1 Day 3 to Day 9 (0 to 144 hrs post-dose)
Query!
Secondary outcome [2]
0
0
Plasma Pharmacokinetics (PK) Parameter of Daunorubicinol: Half-life (t1/2)
Query!
Assessment method [2]
0
0
Daunorubicinol half-life. PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.
Query!
Timepoint [2]
0
0
Cycle 1 Day 3 to Day 9 (0 to 144 hrs post-dose)
Query!
Secondary outcome [3]
0
0
Daunorubicin Dose-normalized Plasma: AUC(0-8)
Query!
Assessment method [3]
0
0
Daunorubicin AUC(0-8). PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.
Query!
Timepoint [3]
0
0
Cycle 1 Day 3 to Day 9 (0 to 144 hrs post-dose)
Query!
Secondary outcome [4]
0
0
Daunorubicinol Dose-normalized Plasma: AUC(0-8)
Query!
Assessment method [4]
0
0
Daunorubicinol AUC(0-8). PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.
Query!
Timepoint [4]
0
0
Cycle 1 Day 3 to Day 9 (0 to 144 hrs post-dose)
Query!
Secondary outcome [5]
0
0
Daunorubicin Dose-normalized Plasma: AUC(24-8)
Query!
Assessment method [5]
0
0
Daunorubicin AUC(24-8). PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.
Query!
Timepoint [5]
0
0
Cycle 1 Day 4 to Day 9 (24 to 144 hrs post-dose)
Query!
Secondary outcome [6]
0
0
Daunorubicinol Dose-normalized Plasma: AUC(24-8)
Query!
Assessment method [6]
0
0
Daunorubicinol AUC(24-8). PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.
Query!
Timepoint [6]
0
0
Cycle 1 Day 4 to Day 9 (24 to 144 hrs post-dose)
Query!
Secondary outcome [7]
0
0
Daunorubicin Dose-normalized Plasma: AUC(0-t)
Query!
Assessment method [7]
0
0
Daunorubicin AUC(0-t). PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.
Query!
Timepoint [7]
0
0
Cycle 1 Day 3 to Day 9 (0 to 144 hrs post-dose)
Query!
Secondary outcome [8]
0
0
Daunorubicinol Dose-normalized Plasma: AUC(0-t)
Query!
Assessment method [8]
0
0
daunorubicinol AUC(0-t). PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.
Query!
Timepoint [8]
0
0
Cycle 1 Day 3 to Day 9 (0 to 144 hrs post-dose)
Query!
Secondary outcome [9]
0
0
Daunorubicin Dose-normalized Plasma: AUC(24-t)
Query!
Assessment method [9]
0
0
Daunorubicin AUC(24-t). PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.
Query!
Timepoint [9]
0
0
Cycle 1 Day 4 to Day 9 (24 to 144 hrs post-dose)
Query!
Secondary outcome [10]
0
0
Daunorubicinol Dose-normalized Plasma: AUC(24-t)
Query!
Assessment method [10]
0
0
Daunorubicinol AUC(24-t). PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.
Query!
Timepoint [10]
0
0
Cycle 1 Day 4 to Day 9 (24 to 144 hrs post-dose)
Query!
Secondary outcome [11]
0
0
Daunorubicin Dose-normalized Plasma: Cmax
Query!
Assessment method [11]
0
0
Daunorubicin Cmax. PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.
Query!
Timepoint [11]
0
0
Cycle 1 Day 3 to Day 9 (0 to 144 hrs post-dose)
Query!
Secondary outcome [12]
0
0
Daunorubicinol Dose-normalized Plasma: Cmax
Query!
Assessment method [12]
0
0
Daunorubicinol Cmax. PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.
Query!
Timepoint [12]
0
0
Cycle 1 Day 3 to Day 9 (0 to 144 hrs post-dose)
Query!
Secondary outcome [13]
0
0
Cycle 2: Daunorubicin Dose-normalized Plasma: AUC(0-24)
Query!
Assessment method [13]
0
0
Cycle 2 Daunorubicin AUC(0-24). PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.
Query!
Timepoint [13]
0
0
Cycle 2 Day 1 to Day 2 (0 to 24 post-dose)
Query!
Secondary outcome [14]
0
0
Cycle 2: Daunorubicinol Dose-normalized Plasma: AUC(0-24)
Query!
Assessment method [14]
0
0
Cycle 2 Daunorubicinol AUC(0-24). PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.
Query!
Timepoint [14]
0
0
Cycle 2 Day 1 to Day 2 (0 to 24 post-dose)
Query!
Secondary outcome [15]
0
0
Cycle 2: Daunorubicin Dose-normalized Plasma: Cmax
Query!
Assessment method [15]
0
0
Cycle 2 Daunorubicin Cmax. PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.
Query!
Timepoint [15]
0
0
Cycle 2 Day 1 to Day 2 (0 to 24 post-dose)
Query!
Secondary outcome [16]
0
0
Cycle 2: Daunorubicinol Dose-normalized Plasma: Cmax
Query!
Assessment method [16]
0
0
Cycle 2 Daunorubicinol Cmax. PK analyses used actual relative time and actual dosing information in mg/m2. All parameter values were divided by daunorubicin dose in mg/m2 except t1/2.
Query!
Timepoint [16]
0
0
Cycle 2 Day 1 to Day 2 (0 to 24 post-dose)
Query!
Secondary outcome [17]
0
0
Number of Platelet Transfusions Per Week Within Cycles
Query!
Assessment method [17]
0
0
This was the average number of platelet transfusions per week within cycles.
Query!
Timepoint [17]
0
0
Post-Base line up to Day 42 of the latest chemotherapy cycle (Up to 8 weeks)
Query!
Secondary outcome [18]
0
0
Time to Platelet Count Recovery >=20 Gi/L
Query!
Assessment method [18]
0
0
Time to Platelet counts >= 20 Gi/L for 3 consecutive days, unaided by transfusions in patients with < 20 Gi/L after chemotherapy. For this endpoint, the event required platelet count to be >= 20 Gi/L for 3 consecutive days. Hematology was assessed daily during hospital stay but only weekly after hospital discharge and thus, platelet count was not always available for 3 consecutive days to confirm the achievement of platelet count recovery.
Query!
Timepoint [18]
0
0
From last dose of chemotherapy to up to end of study year 2 assessment
Query!
Secondary outcome [19]
0
0
Time to Platelet Recovery >=100 Gi/L
Query!
Assessment method [19]
0
0
Time to platelet counts >= 100 Gi/L unaided by transfusions in participants with < 100 Gi/L after chemotherapy.
Query!
Timepoint [19]
0
0
From last dose of chemotherapy to up to end of study year 2 assessment
Query!
Secondary outcome [20]
0
0
Number of Participants Who Achieved Platelet Count Recovery by Day 21
Query!
Assessment method [20]
0
0
Number of participants with platelet counts 20 Gi/L for 3 consecutive days, unaided by transfusions, in patients with < 20 Gi/L after chemotherapy.
Query!
Timepoint [20]
0
0
By Day 21
Query!
Secondary outcome [21]
0
0
Summary of Platelet Counts Over Time
Query!
Assessment method [21]
0
0
Platelet counts over time
Query!
Timepoint [21]
0
0
Baseline, daily then weekly within cycle up to 42 days after last chemotherapy dose, end of therapy /remission assessment visit
Query!
Secondary outcome [22]
0
0
Maximum Duration (Days) of Platelet Transfusion Independence
Query!
Assessment method [22]
0
0
Maximum time period (in days) during which the patient did not receive any platelet transfusion
Query!
Timepoint [22]
0
0
At differnt time points from start of treatment and up to end of study year 2 assessment
Query!
Secondary outcome [23]
0
0
Percentage of Patients Who Achieved Platelet Transfusion Independence = 28 Days
Query!
Assessment method [23]
0
0
Percentage of patients who achieved platelet transfusion independence = 28 days.
Query!
Timepoint [23]
0
0
From start of treatment and up to end of study year 2 assessment
Query!
Secondary outcome [24]
0
0
Time to Neutrophil Engraftment
Query!
Assessment method [24]
0
0
Time to absolute neutrophil count (ANC) >= 0.5 Gi/L for 3 consecutive days in participants with ANC < 0.5 Gi/L after chemotherapy
Query!
Timepoint [24]
0
0
At different time points from last dose of chemotherapy up to end of study year 2 assessment
Query!
Secondary outcome [25]
0
0
Summary of Absolute Neutrophil Counts (ANC)
Query!
Assessment method [25]
0
0
Absolute neutrophil counts over time
Query!
Timepoint [25]
0
0
Baseline, daily then weekly within cycle up to 42 days after last chemotherapy dose, end of therapy /remission assessment visit
Query!
Secondary outcome [26]
0
0
Summary of Hemoglobin
Query!
Assessment method [26]
0
0
Hemoglobin level over time
Query!
Timepoint [26]
0
0
Baseline, daily then weekly within cycle up to 42 days after last chemotherapy dose, end of therapy /remission assessment visit
Query!
Secondary outcome [27]
0
0
Incidence of Hemorrhagic Events
Query!
Assessment method [27]
0
0
Incidence of bleeding events using WHO bleeding grade (G0=No bleeding, G1=Petechiae, G2=Mild blood loss, G3=Gross blood loss, G4=Debilitating blood loss) by week and cycle
Query!
Timepoint [27]
0
0
Baseline, weekly within induction and re-induction cycles, end of therapy
Query!
Secondary outcome [28]
0
0
Percentage of Participants With Disease Response Rate and Type of Response
Query!
Assessment method [28]
0
0
Disease response as assessed by the investigator using the AML International Working Group Response Assessment at the end of therapy/remission assessment visit; Complete remission (CR): defined as transfusion independence, blood count recovery (Abs. neutrophil count > 1.0 Gi/L and Platelet count > 100.0 Gi/L), no leukemic blast in peripheral blood, Bone Marrow (BM) blasts < 5%, maturation of all cell lines, Auer rods not detectable, and no extramedullary disease.
Partial remission (PR): defined as CR except that for BM blasts where a decrease of at least 50% of BM blasts to 5-25% in BM aspirate is sufficient or BM blasts < 5% with Auer rods present.
Overall response (OR) = CR + PR.
Query!
Timepoint [28]
0
0
Day 42 of the latest chemotherapy cycle (Up to 8 weeks)
Query!
Secondary outcome [29]
0
0
Overall Survival (OS)
Query!
Assessment method [29]
0
0
Overall survival defined as the time form randomization until the date of death due to any cause.
Query!
Timepoint [29]
0
0
From randomization to end of 2-year follow-up
Query!
Secondary outcome [30]
0
0
Number of Participants Who Required Medical Resource Utilization
Query!
Assessment method [30]
0
0
Medical Resource Utilization pertained to unscheduled hospitalizations, unscheduled office visits, unscheduled laboratory tests, and unscheduled procedures.
Query!
Timepoint [30]
0
0
At screening and from start of treatment to end of therapy/remission assessment visit (Day 42 of the latest chemotherapy cycle)
Query!
Eligibility
Key inclusion criteria
Inclusion Criteria
- Age >=18 years
- Diagnosed with AML according to the WHO 2008 classification. Note: subjects with
secondary AML following Myelodysplastic syndrome or secondary to previous leukemogenic
therapy are allowed provided that a record of previous MDS history or leukemogenic
therapy history is available.
- Eligible for induction by daunorubicin + cytarabine.
- Eligible to give informed consent to participate in the study.
- Have adequate baseline organ function defined by the following criteria:
Total bilirubin <=1.5 x upper limit of normal (ULN) except for Gilbert's syndrome, or other
conditions that are not indicative of inadequate liver function (i.e. elevation of indirect
bilirubin (haemolytic) in the absence of alanine aminotransferase [ALT] abnormality).
ALT <=3 x ULN. Serum Creatinine <=2.5 x ULN.
- Adequate cardiac function with LVEF >=50% as assessed by echocardiogram (ECHO) or
Multi Gated Acquisition Scan (MUGA.
- Subjects with a QT interval corrected for heart rate according to Bazett's formula
(QTcB) <450millisecond (msec) or <480msec for subjects with bundle branch block. The
QTc should be based on single or averaged QTc values of triplicate electrocardiograms
(ECGs) obtained over a brief recording period.
- Women must be either of non-childbearing potential or women with child-bearing
potential and men with reproductive potential must be willing to practice acceptable
methods of birth control during the study.
- Men with a female partner of childbearing potential must have either had a prior
vasectomy or agree to use effective contraception from time of randomization until 30
days after the last dose of investigational product.
- Women of childbearing potential must have a negative serum pregnancy test within 7
days of first dose of study treatment and agree to use effective contraception during
the study and for 30 days following the last dose of investigational product.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion Criteria
- A diagnosis of acute promyelocytic (M3) or acute megakaryocytic leukaemia (M7).
- Previous history of exposure to an anthracycline compound.
- Previous AML treatment (other than hydroxyurea).
- Any serious medical condition, laboratory abnormality, or psychiatric illness that, in
the view of the treating physician, would place the participant at an unacceptable
risk if he or she were to participate in the study or would prevent that person from
giving informed consent.
- History of thromboembolic event or other condition requiring ongoing use of
anticoagulation either with warfarin or low molecular-weight heparin. Note: Occlusion
of a central line is not exclusion.
- Treatment with an investigational drug within 30 days or 5 half lives, whichever is
longer, preceding the first dose of study medication.
- Current and continued use during study treatment period of known Breast cancer
resistance protein (BCRP) inhibitors or known P-gp inhibitors.
- Known active hepatitis B, hepatitis C or Human Immunodeficiency Virus (HIV) infection.
- Known hypersensitivity to any of the study drugs or its excipients.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
5/09/2013
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
25/01/2017
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
148
Query!
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Query!
Recruitment hospital [1]
0
0
Novartis Investigative Site - Kogarah
Query!
Recruitment hospital [2]
0
0
Novartis Investigative Site - Melbourne
Query!
Recruitment hospital [3]
0
0
Novartis Investigative Site - Parkville
Query!
Recruitment postcode(s) [1]
0
0
2217 - Kogarah
Query!
Recruitment postcode(s) [2]
0
0
3004 - Melbourne
Query!
Recruitment postcode(s) [3]
0
0
3050 - Parkville
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Connecticut
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Florida
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Georgia
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Iowa
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Massachusetts
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Missouri
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
New York
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
North Carolina
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Ohio
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Pennsylvania
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Rhode Island
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Tennessee
Query!
Country [13]
0
0
Belgium
Query!
State/province [13]
0
0
Bruxelles
Query!
Country [14]
0
0
Belgium
Query!
State/province [14]
0
0
Leuven
Query!
Country [15]
0
0
Canada
Query!
State/province [15]
0
0
Ontario
Query!
Country [16]
0
0
Canada
Query!
State/province [16]
0
0
Quebec
Query!
Country [17]
0
0
Greece
Query!
State/province [17]
0
0
Athens
Query!
Country [18]
0
0
Greece
Query!
State/province [18]
0
0
Patra
Query!
Country [19]
0
0
Hungary
Query!
State/province [19]
0
0
Debrecen
Query!
Country [20]
0
0
Hungary
Query!
State/province [20]
0
0
Szeged
Query!
Country [21]
0
0
Israel
Query!
State/province [21]
0
0
Haifa
Query!
Country [22]
0
0
Israel
Query!
State/province [22]
0
0
Holon
Query!
Country [23]
0
0
Israel
Query!
State/province [23]
0
0
Jerusalem
Query!
Country [24]
0
0
Israel
Query!
State/province [24]
0
0
Kfar Saba
Query!
Country [25]
0
0
Israel
Query!
State/province [25]
0
0
Tel-Aviv
Query!
Country [26]
0
0
Korea, Republic of
Query!
State/province [26]
0
0
Seoul, Korea
Query!
Country [27]
0
0
Korea, Republic of
Query!
State/province [27]
0
0
Seoul
Query!
Country [28]
0
0
Poland
Query!
State/province [28]
0
0
Slupsk
Query!
Country [29]
0
0
Poland
Query!
State/province [29]
0
0
Wroclaw
Query!
Country [30]
0
0
Russian Federation
Query!
State/province [30]
0
0
Kaluga
Query!
Country [31]
0
0
Russian Federation
Query!
State/province [31]
0
0
Moscow
Query!
Country [32]
0
0
Russian Federation
Query!
State/province [32]
0
0
Nizhniy Novgorod
Query!
Country [33]
0
0
Russian Federation
Query!
State/province [33]
0
0
Penza
Query!
Country [34]
0
0
Russian Federation
Query!
State/province [34]
0
0
St'Petersburg
Query!
Country [35]
0
0
Russian Federation
Query!
State/province [35]
0
0
Tula
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Novartis Pharmaceuticals
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this randomized, blinded, placebo-controlled study was to provide clinical
safety and exploratory efficacy data on the use of Eltrombopag in adult subjects with Acute
Myeloid Leukemia (AML) receiving standard induction chemotherapy with daunorubicin plus
cytarabine. A minimum of 120 evaluable subjects newly diagnosed with AML was stratified by
antecedent malignant hematologic disorder and age.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01890746
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Novartis Pharmaceuticals
Query!
Address
0
0
Novartis Pharmaceuticals
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01890746
Download to PDF